etanidazole has been researched along with Local Neoplasm Recurrence in 6 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation." | 2.73 | A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02). ( Cmelak, AJ; Drzymala, RE; Loeffler, J; Shaw, E; Souhami, L; Wasserman, TH; Won, M, 2008) |
| "Etanidazole was given via intravenous infusion over 15 minutes, followed within 20 to 30 minutes by intraoperative radiation therapy." | 2.67 | RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies. ( Buswell, L; Coleman, CN; Cosmatis, D; Gunderson, LL; Halberg, FE; Hanks, GR; Nagorney, DM; Noyes, RD, 1994) |
| "Patients with soft tissue sarcomas of the head and neck, extremity, trunk, or retroperitoneum for whom surgical excision was the initial treatment of choice, were given 21 mg/kg EF5 24-48 hours before surgery." | 1.33 | EF5 binding and clinical outcome in human soft tissue sarcomas. ( Evans, SM; Fraker, D; Gleason, K; Hahn, SM; Hwang, WT; Jenkins, K; Jenkins, WT; Koch, CJ; Mick, R; Zhang, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qian, Y | 1 |
| Von Eyben, R | 1 |
| Liu, Y | 1 |
| Chin, FT | 1 |
| Miao, Z | 1 |
| Apte, S | 1 |
| Carter, JN | 1 |
| Binkley, MS | 1 |
| Pollom, EL | 1 |
| Harris, JP | 1 |
| Prionas, ND | 1 |
| Kissel, M | 1 |
| Simmons, A | 1 |
| Diehn, M | 1 |
| Shultz, DB | 1 |
| Brown, JM | 1 |
| Maxim, PG | 1 |
| Koong, AC | 1 |
| Graves, EE | 1 |
| Loo, BW | 1 |
| Evans, SM | 2 |
| Judy, KD | 1 |
| Dunphy, I | 1 |
| Jenkins, WT | 2 |
| Hwang, WT | 2 |
| Nelson, PT | 1 |
| Lustig, RA | 1 |
| Jenkins, K | 2 |
| Magarelli, DP | 1 |
| Hahn, SM | 2 |
| Collins, RA | 1 |
| Grady, MS | 1 |
| Koch, CJ | 2 |
| Fraker, D | 1 |
| Gleason, K | 1 |
| Zhang, P | 1 |
| Mick, R | 1 |
| Drzymala, RE | 1 |
| Wasserman, TH | 1 |
| Won, M | 1 |
| Shaw, E | 1 |
| Cmelak, AJ | 1 |
| Loeffler, J | 1 |
| Souhami, L | 1 |
| Bornstein, BA | 1 |
| Zouranjian, PS | 1 |
| Hansen, JL | 1 |
| Fraser, SM | 1 |
| Gelwan, LA | 1 |
| Teicher, BA | 1 |
| Svensson, GK | 1 |
| Halberg, FE | 1 |
| Cosmatis, D | 1 |
| Gunderson, LL | 1 |
| Noyes, RD | 1 |
| Hanks, GR | 1 |
| Buswell, L | 1 |
| Nagorney, DM | 1 |
| Coleman, CN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer[NCT01881451] | 5 participants (Actual) | Observational | 2013-08-31 | Terminated (stopped due to Due to slow accrual and access to the study drug.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for etanidazole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Etanidazole; Humans; Neoplasm Recurrence, Local; | 2008 |
RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies.
Topics: Adolescent; Adult; Aged; Cell Hypoxia; Combined Modality Therapy; Etanidazole; Evaluation Studies as | 1994 |
4 other studies available for etanidazole and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Topics: Aged; Aged, 80 and over; Etanidazole; Female; Fluorine Radioisotopes; Humans; Hydrocarbons, Fluorina | 2018 |
Hypoxia is important in the biology and aggression of human glial brain tumors.
Topics: Aged; Brain Neoplasms; Electrodes; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypoxia; | 2004 |
EF5 binding and clinical outcome in human soft tissue sarcomas.
Topics: Adult; Aged; Cell Hypoxia; Etanidazole; Female; Humans; Hydrocarbons, Fluorinated; Indicators and Re | 2006 |
Local hyperthermia, radiation therapy, and chemotherapy in patients with local-regional recurrence of breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neopl | 1993 |